Journal
IMMUNOTHERAPY
Volume 2, Issue 1, Pages 99-115Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.09.61
Keywords
disease-modifying treatment; experimental autoimmune encephalomyelitis; immune system; immunotherapy; multiple sclerosis; T cell
Categories
Funding
- NINDS NIH HHS [R01 NS046782, R01 NS046782-05A2] Funding Source: Medline
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046782] Funding Source: NIH RePORTER
Ask authors/readers for more resources
One of the reasons multiple sclerosis (MS) has been considered a T-cell mediated autoimmune disease is that a similar experimental disease can be induced in certain rodents and primates by immunization with myelin antigens, leading to T-cell-mediated inflammatory demyelination in the CNS. In addition, most if not all pharmacological treatments available for MS are biologically active on T cells. In this article we review the principles of T-cell-based immunotherapies and the specific actions of current and novel treatments on T-cell functions, when these are known. For both licensed and innovative agents, we also discuss biological actions on other immune cell types. Finally, we offer a brief perspective on expected changes in the use of MS immunotherapies in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available